We are live on
!
Find out more
BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
1-Year Est. Return
11.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.15%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$717M
AUM Growth
–
Cap. Flow
+$692M
Cap. Flow
% of AUM
96.53%
Top 10 Holdings %
Top 10 Hldgs %
28.85%
Holding
141
New
141
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$27.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$27M |
| 3 |
Medtronic
MDT
|
+$25.8M |
| 4 |
Gilead Sciences
GILD
|
+$23.7M |
| 5 |
Abbott
ABT
|
+$23.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.25% |
| 2 | Financials | 0.88% |
| 3 | Industrials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$9.46B
| $9.36M | 1.31% |
+147,000
| New | +$9.97M |
|
27
McKesson
MCK
$103B
| $9.27M | 1.29% |
+41,000
| New | +$9.09M |
|
|
MNK
28
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $8.87M | 1.24% |
+70,000
| New | +$8M |
|
29
Teva Pharmaceuticals
TEVA
$42.1B
| $8.72M | 1.22% |
+140,000
| New | +$8.14M |
|
30
Becton Dickinson
BDX
$48.9B
| $8.42M | 1.17% |
+60,073
| New | +$8.41M |
|
31
Cardinal Health
CAH
$55.5B
| $8.12M | 1.13% |
+90,000
| New | +$7.75M |
|
32
Incyte
INCY
$24.6B
| $8.1M | 1.13% |
+88,352
| New | +$7.3M |
|
|
RCPT
33
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $7.92M | 1.1% |
+48,000
| New | +$6.07M |
|
34
Acadia Pharmaceuticals
ACAD
$5.06B
| $7.53M | 1.05% |
+231,000
| New | +$7.94M |
|
35
Ligand Pharmaceuticals
LGND
$6.42B
| $7.18M | 1% |
+149,335
| New | +$5.72M |
|
36
Boston Scientific
BSX
$73.1B
| $7.17M | 1% |
+404,000
| New | +$6.38M |
|
|
MDVN
37
DELISTED
MEDIVATION, INC.
MDVN
| $7.01M | 0.98% |
+108,600
| New | +$6.22M |
|
|
AKRX
38
DELISTED
Akorn Inc
AKRX
| $6.89M | 0.96% |
+145,000
| New | +$6.58M |
|
39
Intuitive Surgical
ISRG
$139B
| $6.84M | 0.95% |
+121,950
| New | +$6.9M |
|
40
Alnylam Pharmaceuticals
ALNY
$29B
| $6.68M | 0.93% |
+64,000
| New | +$6.49M |
|
|
LCI
41
DELISTED
Lannett Company, Inc.
LCI
| $6.61M | 0.92% |
+24,388
| New | +$5.54M |
|
42
Molina Healthcare
MOH
$10.4B
| $6.39M | 0.89% |
+94,960
| New | +$5.49M |
|
|
AET
43
DELISTED
Aetna Inc
AET
| $6.29M | 0.88% |
+59,000
| New | +$5.78M |
|
44
Pfizer
PFE
$154B
| $6.26M | 0.87% |
+189,720
| New | +$6.03M |
|
45
Cigna
CI
$73.6B
| $5.83M | 0.81% |
+45,000
| New | +$5.23M |
|
46
Dr. Reddy's Laboratories
RDY
$10.1B
| $5.71M | 0.8% |
+500,000
| New | +$5.3M |
|
47
Agios Pharmaceuticals
AGIO
$1.95B
| $5.47M | 0.76% |
+58,000
| New | +$6.5M |
|
48
Alkermes
ALKS
$8.29B
| $5.27M | 0.74% |
+86,500
| New | +$5.91M |
|
49
Brookdale Senior Living
BKD
$3.27B
| $5.07M | 0.71% |
+134,140
| New | +$4.91M |
|
50
HCA Healthcare
HCA
$89.6B
| $5.04M | 0.7% |
+67,000
| New | +$4.81M |
|
Similar funds
VFAM
MSU
PSI
SFP
MCM
NMIS
SM
ZAM
Bellevue Asset Management (Switzerland)'s Q1 2015 Portfolio in Review
Q1 2015 is the first quarter with a 13F filing on record for Bellevue Asset Management (Switzerland), which disclosed 141 positions worth $717M. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Biogen: 70,730 shares worth $29.9M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Financials and Industrials.
- Bellevue Asset Management (Switzerland)'s largest Q1 2015 buy was Biogen: 70,730 shares worth $29.9M.
- Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $717M portfolio in Q1 2015.
- Bellevue Asset Management (Switzerland) disclosed 141 positions in Q1 2015, its first 13F filing on record.
Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q1 2015, filed 14 May 2015.